

HCG introduces USFDA approved digital pathology solution across India

26 April 2019 | News

The technology will ensure faster and accurate diagnosis, improving the quality of life of patients



HCG- The Specialist in Cancer Care has introduced USFDA approved Digital Pathology Solution by Philips Intellisite Pathology Solutions across all its centres in India.

This state-of-the-art technology marks a major step forward in cancer treatment through precision, speed, efficiency and ease of use with immense potential to provide significant clinical benefits to both the physicians and patients.

HCG began using the digital solution from October 2018 onwards, gradually adding it to all its centres post successful validation and integration of the system in the workflow. The official launch of the digital solution by HCG took place recently in Bengaluru.

“Pathological diagnosis is one of the most important steps in oncology and at HCG, we have always believed in organ specific pathologists reviewing the samples. With digital pathology, the way the samples are presented and its magnification are infinitely better than the human eye reviewing them. The best advantage is that several people can review the slides at the same time, in countries like India and Africa, where it may be difficult for patients to get expertise. Digital pathology can bridge this gap”, said Dr BS Ajaikumar, Chairman & CEO, HCG Enterprises at the launch.